-
Merck Completes Tender Offer to Acquire Immune Design
Post on 4/2/19
-
Valeritas Partners with the American Association of Diabetes Educators
Post on 4/1/19
-
Amneal Announces Agreement with Zentiva to Divest Creo Pharma
Post on 4/1/19
-
Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market
Post on 4/1/19
-
Salix Enters Into License Agreement With The University Of California
Post on 4/1/19
-
Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS
Post on 4/1/19
-
Better Buy: AbbVie vs. Johnson & Johnson
Post on 4/1/19
-
Realm Therapeutics Announces Completion of Assets Disposal
Post on 3/31/19
-
Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks?
Post on 3/29/19
-
ECRI Institute Opens International Medical Device Evaluation Center
Post on 3/28/19
-
Advaxis Announces Reverse Stock Split
Post on 3/28/19
-
Mitsubishi Tanabe Pharma America Announces Collaboration With Massachusetts General Hospital On ALS Biomarker Study
Post on 3/28/19
-
GenScript to Fund Generation of First Sustainable Drosophila Antibody Library
Post on 3/28/19
-
Johnson & Johnson Vs. Pfizer: Which Big Pharma Giant Is The Better Dividend Stock?
Post on 3/27/19
-
Men's Health Honors Eggland's Best with 2019 Best Foods for Men Award
Post on 3/26/19
-
Legal Battle Against Opioid Crisis Heats Up
Post on 3/26/19
-
Celgene/Bristol-Myers Merger: The Arb Spread Continuum Offers Clues
Post on 3/26/19
-
Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal
Post on 3/26/19
-
Interview with Nick Ciccarelli, President of Neuma, LLC - Part III
Post on 4/11/19
-
Interview with Nick Ciccarelli, President of Neuma, LLC - Part II
Post on 4/8/19
-
Interview with Nick Ciccarelli, President of Neuma, LLC - Part I
Post on 4/3/19
-
Titan Medical and Teleflex Incorporated Announce Collaboration
Post on 3/25/19
-
Bristol-Myers Squibb Board Sends Letter to Shareholders Regarding Merger With Celgene
Post on 3/25/19
-
2019’s Best & Worst States for Doctors – WalletHub Study
Post on 3/25/19
-
Merck Portfolio: Halftime Report
Post on 3/25/19